乳房隆突术术后急性疼痛:四种镇痛方案比较
单中心回顾性研究纳入132例乳房隆突术患者,比较布比卡因、布比卡因+脂质体布比卡因、加术中酮咯酸、加术后酮咯酸四组镇痛方案。术中酮咯酸组出院时疼痛评分最低(P<0.0001)且接受麻醉药比例最低(P=0.009),PACU停留时间、术后即刻疼痛及止吐药用量无显著差异,无出血并发症。
要点
- 术中酮咯酸可降低乳房隆突术患者出院时疼痛及麻醉药使用比例。
- 脂质体布比卡因在短恢复期手术中可能不提供额外获益。
- 四组PACU停留时间、术后即刻疼痛及止吐药用量无显著差异。
核心结论
- 乳房隆突术镇痛方案中应考虑加入术中酮咯酸,因其显著降低麻醉药使用和出院时疼痛。
- 脂质体布比卡因等昂贵药物在短恢复期手术的术后即刻设置中可能不提供额外获益。
研究设计与样本
- 单中心回顾性研究,共纳入132例患者。
- 比较四组:仅布比卡因(B)、布比卡因+脂质体布比卡因(BL)、BL+术中酮咯酸(BLKi)、BL+术后酮咯酸(BLKp)。
主要发现
- 术中酮咯酸组出院时疼痛评分最低(P<0.0001)。
- 术中酮咯酸组接受麻醉药患者比例最低(P=0.009)。
- 四组PACU停留时间、术后即刻疼痛、止吐药用量无显著差异。
- 接受与未接受酮咯酸者均未观察到出血并发症。
关键数值与推荐
- 出院时疼痛评分:术中酮咯酸组最低,P<0.0001。
- 接受麻醉药比例:术中酮咯酸组最低,P=0.009。
临床怎么用
- 乳房隆突术可考虑术中给予酮咯酸以改善出院时疼痛并减少麻醉药使用。
- 短恢复期手术中脂质体布比卡因的常规添加需权衡成本与获益。
局限性
- 单中心回顾性设计可能引入选择偏倚。
- 样本量132例,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients undergoing breast augmentation are treated with multiple combinations of medications for pain control including ketorolac, liposomal bupivacaine, bupivacaine, and intravenous and oral narcotics. There is no current consensus on the optimal combination; therefore, all are used at the discretion of the surgeon. METHODS: This was a single-center, retrospective study. The total number of patients included was 132. Comparisons were made between 4 groups: bupivacaine only (B); bupivacaine and liposomal bupivacaine (BL); bupivacaine and liposomal bupivacaine plus intraoperative ketorolac (BLKi); and bupivacaine and liposomal bupivacaine plus postoperative ketorolac (BLKp). Average pain scores immediately postoperative and before discharge were recorded and correlated to percentage of patients who received narcotic in the post-anesthesia care unit (PACU). Additional end points noted were side effects including nausea and time spent in PACU postoperatively. RESULTS: Those receiving intraoperative ketorolac had the lowest pain on discharge (P < 0.0001) and the lowest percentage of patients receiving narcotics (P = 0.009) out of all 4 groups. There was no significant difference between the 4 groups in terms of time spent in PACU, pain immediately after the procedure, or amount of antiemetic given. No bleeding complications were noted for those who did or did not receive ketorolac. CONCLUSIONS: When given options for pain control in breast augmentation, intraoperative ketorolac should be considered, because its inclusion was significant in decreasing use of narcotics and pain upon discharge. Addition of other costly drugs such as liposomal bupivacaine may not provide additional benefit in the immediate postoperative setting for procedures with a short recovery period such as breast augmentation.
引用
- Tan P, Martin MS, Shank N, et al. A Comparison of 4 Analgesic Regimens for Acute Postoperative Pain Control in Breast Augmentation Patients. Ann Plast Surg. 2017. PMID: 28459704. doi:10.1097/SAP.0000000000001132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。